Please check your internet connection and try again.
# Clobazam (Oral Formulation)
## Overview
Clobazam is a benzodiazepine derivative with anticonvulsant properties. It is primarily used as an adjunctive therapy for seizures associated with Lennox-Gastaut syndrome (LGS).
## Primary Indications
* Adjunctive treatment of seizures in patients with Lennox-Gastaut syndrome (LGS).
## Adult Dosing
* **Initial dose:** 5 mg twice daily.
* **Titration:** Increase dose gradually based on clinical response and tolerability, not more often than every 3 days.
* **Usual maintenance dose:** 10 mg to 20 mg twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
## Pediatric Dosing (2 years and older)
* **Initial dose:** 5 mg once daily.
* **Titration:** Increase dose gradually based on clinical response and tolerability, not more often than every 3 days.
* **Usual maintenance dose:** 10 mg to 20 mg twice daily, may be given once daily or divided twice daily.
* **Maximum dose:** 20 mg twice daily (40 mg/day).
* **Note:** Dosing for children under 2 years of age is not established.
## Dose Adjustments
* **Hepatic Impairment:** Use with caution; no specific dose reduction guidelines are established, but starting at the lower end of the dosing range and titrating slowly is recommended.
* **Renal Impairment:** Use with caution; no specific dose reduction guidelines are established, but starting at the lower end of the dosing range and titrating slowly is recommended.
## Contraindications
* Hypersensitivity to clobazam or other benzodiazepines.
## Adverse Effects
Common adverse effects include somnolence, decreased appetite, constipation, aggression, irritability, upper respiratory tract infection, drooling, and ataxia. Serious adverse effects can include severe skin reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis), withdrawal symptoms upon discontinuation, and potential for dependence.
## Key Drug Interactions
* **CNS Depressants (e.g., alcohol, opioids, other benzodiazepines, sedatives/hypnotics):** Additive CNS depression.
* **CYP2C19 Substrates:** Clobazam is a moderate inhibitor of CYP2C19. Concomitant use with CYP2C19 substrates may increase their plasma concentrations and risk of toxicity (e.g., omeprazole, diazepam).
* **CYP3A4 Inducers/Inhibitors:** May affect clobazam levels.
## Monitoring
* Monitor for therapeutic efficacy (seizure frequency).
* Monitor for adverse effects, particularly somnolence, behavioral changes, and signs of severe skin reactions.
* Monitor for signs of withdrawal if discontinued.
* Consider monitoring drug levels if efficacy is suboptimal or toxicity is suspected, though routine therapeutic drug monitoring is not typically recommended.
## Clinical Pearls
* Clobazam should be tapered slowly upon discontinuation to minimize withdrawal symptoms.
* Due to its long half-life, it may be dosed once or twice daily.
* Consider CYP2C19 genotype for patients on other CYP2C19 substrates where clobazam may be co-administered.
***
*This information is intended for clinical use and does not replace professional medical advice. Always consult the most current prescribing information and relevant clinical guidelines before making treatment decisions.*
